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Aim: The purpose of the present study was to evaluate the feasibility of sentinel
node biopsy (SNB) in lymph node staging in breast cancer with a special empha-
sis on radioguided occult lesion localization (ROLL), hospital costs, and post-
operative morbidity.
Patients and methods: The study population comprised of clinically stage T1-2
and node-negative breast cancer patients, who underwent breast surgery and SNB
between 31 May 2000 and 28 February 2002 at the Breast Surgery Unit, Helsin-
ki University Hospital. Preoperative lymphoscintigraphy (LS), intraoperative gam-
ma probe, and blue dye were used for identification of sentinel nodes (SNs).
Axillary clearance (AC) was performed when the SNs in the axilla were involved
or were not identified. Any SN outside level I-II of axilla, when clearly visible in
LS, was also excised. Single intratumoral injection of the radioactive tracer in
ultrasound (US) guidance for nonpalpable tumors visible in US, was the only
tumor localization method (ROLL).
The sequence of the treatment procedures of 237 consecutive patients was
recorded and evaluated by use of three hypothetical scenarios: Diagnostic axillary
lymph node dissection (ALND), SNB without frozen section diagnosis, and SNB
as day-case surgery prior to the breast operation. The total hospital costs were
calculated in all protocols.
One-year breast morbidity was evaluated by clinical examination and breast
ultrasound (US) in 102 patients. To evaluate postoperative arm morbidity, a
physiotherapist examined 83 patients preoperatively and 3,6, and 12 months
postoperatively; the range of shoulder motion on both sides and the sense of
touch in the axillary and breast areas was measured. Self-experienced morbidity
was estimated by a questionnaire concerning postoperative pain, range of shoul-
der motion, numbness, muscle weakness, lymphedema, and sensory disorders.
Results: LS showed SN in the axilla in 88% of the 170 patients, 17% with SN
outside level I–II of the axilla. Axillary metastases were found in 40% of
the patients with SNs outside the axilla; SN outside the axilla were involved in 3%
of all cases. Two patients with extra-axillary node metastases had no axillary me-
tastases.
Excision of the tumors was complete in 93% of all the 215 cases after the
primary operation and in 89% with radioguided occult lesion localization (ROLL).
In addition, at least 10-mm free margins were achieved with ROLL in a primary
operation in 69% of the patients.
The hospital costs per patient were 3750 € by frozen-section diagnosis of
SNs.  Hospital costs per patient would have been 3020 € with the ALND for
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axillary staging, 4087 € without the frozen section, and 4573 € with the “SNB
as day-case surgery” model.  Costs with or without intraoperative frozen-section
diagnosis would have been equal with a false-negative rate of 35%.
One year after surgery, the clinical examination revealed breast edema in 23%
of 57 patients after SNB. US revealed subcutaneous edema and interstitial fluid in
the breast significantly more often after AC. Approximately a quarter of the 43
patients experienced at least mild arm morbidity one year after SNB alone, where-
as half the patients had similar symptoms after AC. None of the patients after
SNB alone received lymph therapy.
Conclusion: SNB is a feasible method in lymph node staging of breast cancer.
Intratumoral tracer injection makes excision of nonpalpalpable tumors possible
without other localization methods. SNB seems to be associated with higher
hospital costs than is diagnostic ALND, but frozen section diagnosis in SNB is
worthwhile as long as the false-negative rate is less than 35%. The risk for severe
morbidity after SNB seems to be low.
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Introduction
The status of the lymph nodes, in the axilla and in the internal mammary chain,
is the most significant prognostic factor for survival in breast cancer (Morrow et
al 1981, Veronesi et al 1985, Noguchi et al 1991). Ten-year survival of 80% to
100% has been reported, when both the axillary and the internal mammary nodes
(IMN) were uninvolved, compared to 24% to 30% survival of patients with me-
tastases in both nodal basins (Veronesi et al 1985, Noguchi et al 1991). The
intermediate 10-year survival rate was approximately 55%, when only one of the
nodal stations was separately affected (Veronesi et al 1985). Furthermore, the
number of involved lymph nodes correlates with survival. When over three nodes
are involved, the 10-year survival can fall from 90% to 27% (Noguchi et al 1991).
Metastases in the axillary lymph nodes are found in about 40% of patients and in
20% to 25% in the internal mammary chain, and in even more than 30% when the
axillary nodes are also involved (Donegan 1977, Morrow et al 1981, Lacour et al
1983, Veronesi et al, 1985).
Axillary lymph node dissection (ALND) has been the gold standard in axil-
lary staging, providing information for decision-making about adjuvant therapy
(Giuliano et al 1994, Albertini et al 1996, O’Hea et al 1998, Veronesi et al
2003). ALND is considered also as a treatment leading to locoregional control,
when the axillary lymph nodes are involved (Bland et al 1999, Axelsson et al
2000). Recently, lymphatic mapping with sentinel node biopsy (SNB) has been
proposed to provide even more accurate lymphatic staging with less morbidity
than with diagnostic axillary clearance (AC), (Giuliano et al 1994, Albertini et al
1996, Krag and Harlow 2003). Therefore, SNB serves as an indicator for axillary
treatment in an increasing number of breast surgery centers.
Since the beginning of the 1990’s the SNB technique has been a major focus
of breast cancer research, although the universal standardized techniques for SNB
are still lacking.
Numerous studies have reported arm morbidity after breast cancer treatment,
with a focus especially on the extent of axillary surgery. A general and widely
known postoperative complication after ALND is morbidity of the upper ex-
tremity (Petrek and Heelan 1998, Duff et al 2001, Ververs et al 2001, Ernst et al
2002, Gosselink et al 2003) including lymphedema, as well as sensory and func-
tional disorders like numbness and motion restrictions of the shoulder joint.
These symptoms manifest among 20% to 80% of women who have undergone
AC and received radiotherapy (RT), (Tasmuth et al 1996, Ververs et al 2001, Yap
et al 2003, Gosselink et al 2003). The risk for breast and upper arm lymphedema
seems to increase after more extensive axillary surgery (Clarke et al 1982, McCor-
mick et al 1989, Senofsky et al 1991, Temple et al 2002) and postoperative RT
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(Clarke et al 1982, McCormick et al 1989, Senofsky 1991, Isaksson and Feuk
2000). Most of these symptoms manifest immediately or up to one year after
surgery, but symptoms can appear until 2 to 5 years after ALND (Warmuth et al
1998, Ernst et al 2002).
A decreased risk for early, late, and long-term morbidity has been expected
after the introduction of SNB without further axillary treatment. The first studies
have reported significantly less arm morbidity after SNB than after AC (Schrenk
et al 2000, Miguel et al 2001, Sener et al 2001, Burak et al 2002, Ernst et al
2002, Haid et al 2002, Temple et al 2002, Blanchard et al 2003, Gosselink et al
2003, Leidenius et al 2003a, Peintinger 2003, Schijven et al 2003). SNB with-
out further axillary treatment is, however, also associated with postoperative
morbidity, but the clinical significance of the SNB-related morbidity is still ob-
scure.
The purpose of the present study was to evaluate the feasibility of sentinel
node biopsy in lymph node staging in breast cancer with a special emphasis on
hospital costs and postoperative morbidity. A further purpose was to study whether
a nonpalpable tumor can be localized by the same intratumoral injection of radi-
oactive tracer used for lymphatic mapping.
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Review of the Literature
1. Breast cancer incidence and survival
Breast cancer is worldwide the most common cancer in women: up to one wom-
an in eight will develop it during her lifetime. The annual incidence in Finland in
2001 was 3646 new cases, and the age-adjusted incidence was 82.7/100 000
(Finnish cancer registry, 2002). The predicted cancer-specific 5-year relative sur-
vival rate for early stage breast cancer is 85% (Finnish Cancer Registry, 2002).
2. Lymph node metastases
Already in the end of the 1800’s, Halsted described the spread of breast cancer from
the primary tumor to the regional lymph nodes and systemic circulation (Bland &
Copeland 2004). The prevalence of axillary lymph node metastases has been 30%
to 40% in all breast cancer patients (Rosen et al 1983, Veronesi et al 1997, Nieweg
et al 2001) and 10% to 18% in T1 tumors (Port et al 1998, Axelsson et al 2000,
Rivadeneira et al 2000, Bland & Copeland 2004). The presence of internal mam-
mary node metastases is strongly related to axillary node involvement. A sole me-
tastasis directly to the internal mammary nodes is rare (Morrow et al 1981, Noguchi
et al 1991). The prevalence of solitary internal mammary metastases varies from 3%
to 20% (Morrow et al 1981, Noguchi et al 1991, Valdés Olmos et al 2001). Al-
though metastasis is considered to proceed stepwise, skip metastases in the axilla
can be found, but in less than 2% of the cases (Rosen et al, 1983). Table 1
Table 1: Prevalence of axillary and internal mammary lymph node metastases in
breast cancer, 1977–2003
Only internal Axillary and
Publications  Axillary  mammary internal mammary
 metastases metastases  i metastases
(%) (%)  (%)
Donegan et al 1977 58.0 2.6 19.0
Veronesi et al 1981 53.0 4.3 16.0
Noguchi et al 1991 41.0 4.8 35.0
Cody et al 1995 38.0 11.0 14.0
Galimberti et al 2003 37.0 2.5 6.3
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Knowledge of lymphatic drainage patterns and tumor cell dissemination is one
of the basic tools in cancer surgery. Introduction of the SN concept clarified how
little is known about the mechanism of lymphatic metastasis (Quan et al 2002,
Bland & Copeland 2004). It is considered to be an orderly progression of tumor
cells within the lymphatic system (Borgstein et al 1997).
The mammary gland is embryologically derived from the ectoderm and devel-
opes within a skin envelope. Lymphatic drainage from the skin of the breast, the
nipple areolar complex, and some of the central portion of the gland occurs via
the superficial subareolar lymphatic plexus. This plexus is in connection with the
deep lymphatic plexus by interconnecting plexuses (Mortimer 1998, Nathanson
et al 2001, Bland & Copeland 2004). Both the dermal and parenchymal or deep-
er lymphatics of the breast drain to the axillary lymph nodes (Nathanson et al
2001).  Lymph drainage can be occluded indirectly by tumor growth or infec-
tion (Mortimer 1998, Bland & Copeland 2004).
Pieter Camber (b. 1722) and Paolo Mascagni (b. 1752) were the first to de-
scribe the lymphatic drainage from the breast to the internal mammary nodes
and pectoral nodes (Bland & Copeland 2004). At the beginning of the twentieth
century the theory of tumor dissemination by lymphatics and bloodstream, was
accepted widely. This formed also the basis for radical mastectomy endorsed by
Halsted (Bland & Copeland 2004). Sappey (1874) has described the superficial
and deep lymphatic draining systems of the breast. Later anatomic studies have
demonstrated that approximately 75% of lymph drainage is directed to the axilla
and 25% to the internal mammary chain (Bundred et al 1994, Uren et al 2001).
Turner-Warwick (1959) produced autoradiographs and detected that axillary and
internal mammary nodes could receive lymph drainage from any quadrant of the
breast Bland & Copeland 2004).
The size of the primary tumor is the most significant predictive factor for
axillary lymph node metastases (Axelsson et al 2000, Rivadeneira et al 2000)
(Table 2). Furthermore, younger age of the patient and poor histologic grade of
the primary tumor increase risk for nodal involvement (Rivadeneira et al 2000).
Axillary involvement is observed mostly at Berg level I of the axilla (see page 16),
substantially elevating risk for the involvement of higher-level lymph nodes (Daniell
et al 1988).
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Table 2: Relationship of tumor size and axillary lymph node metastases in breast
cancer









Data from Bland & Copeland 2004
3. Staging of breast cancer
The classification of breast tumors is based on the TNM system, which includes
histological tumor size (pT), nodal metastases (pN), and distant metastases (pM)
(Table 3 and 4) (Sobin and Wittekind 2002). Originally, the TNM system was
created for grouping patients into different survival and prognostic groups. After-
wards, it has been a pragmatic and evidence-based model for targeting and deter-
mining treatment, providing a uniform approach between different centers (Bland
& Copeland 2004). The last edition of the TNM classification in particular is
considered a reference for lymph nodes status, especially for micrometastases (Sobin
and Wittekind 2002). This new TNM classification in addition includes quantita-
tive criteria for classification of micrometastasis, an issue emerging after introduc-
tion of the SNB. Revisions of the previous staging system are also related to the
number of axillary lymph nodes involved and to the classification of metastases in
level III axillary lymph nodes and lymph nodes in the internal mammary chain.





pT1a >0.1 – < 0.5 cm
pT1b > 0.5 – < 1.0 cm
pT1c > 1.0 – < 2.0cm
pT2 > 2.0 cm – < 5.0cm
pT3 > 5.0cm
pT4 Tumor of any size with direct extension
to chest wall or skin
Data from Sobin and Wittekind, 2002
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Table 4: pN classification of breast cancer based on axillary lymph node dissec-
tion with or without sentinel node biopsy
Classification of regional     
 Status of regional lymph nodes
lymph nodes
pNx Cannot assess
PN0 / PN0(i-) No metastasis / no metastasis histologically, negative IHC
PN0(i+) No metastasis / no metastasis histologically, positive IHC,
no IHC clusters > 0.2 mm
pN0(mol-) No metastasis / no metastasis histologically or molecularly
pN0(mol+) No metastasis / no metastasis histologically, positive
molecular findings
pN1a / pN1b Metastasis in 1–3 axillary lymph nodes and / or IMN
pN1c Metastasis in 1–3 axillary lymph nodes and IMN
pN1mic Micrometastasis >0.2 mm – < 2.0 mm
PN2a / PN2b Metastasis in 4–9 axillary lymph nodes or in IMN
PN3a Metastasis in ≥10 axillary lymph nodes or in infraclavicular
lymph nodes
PN3b Metastasis in ipsilateral IMN and ≥1 positive axillary
lymph nodes or >3 positive axillary lymph nodes and
microscopically defined IMN metastases
PN3c Metastasis in ipsilateral supraclavicular lymph nodes
IHC= immunohistochemistry
IMN= internal mammary nodes
Data from Sobin and Wittekind, 2002
4. Axillary lymph node dissection
ALND has been the gold standard for decades in axillary staging of breast cancer,
providing excellent loco-regional control of the disease and probably also a sur-
vival advantage (Blichert-Toft 2000, Axelsson et al 2000). No imaging tech-
nique or molecular biological marker can replace surgically defined nodal status
thus far (Blichert-Toft 2000).
One of the main basic questions is how many lymph nodes have to be exam-
ined to determine reliably the status of nodes in the nodal basin (Recht and
Houlihan 1995). The extent of axillary surgery is based on the Berg levels of the
axilla: level I (proximal), tissue inferior and lateral to the pectoral minor muscle;
level II (middle/ central), nodes posterior to the pectoral minor muscle and
below the axillary vein; level III (apical), nodes medial to the pectoral minor
muscle against the chest wall (Bundred et al 1994). These levels, taken together,
contain approximately 20 lymph nodes, which are mainly on level I. In general,
level I–II axillary lymph node dissection is performed for staging purposes.
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At least 10 axillary nodes should be examined to reach reliable staging and
loco-regional control, when the axillary nodes are involved. For low- risk tumors
(<10 mm), recurrence rate and recurrence-free survival was significantly better
when at least ten axillary nodes were removed (Axelsson et al 2000). The incidence
of “skip-metastases” has been 0.2% to 3% at level III, without concomitant metas-
tasis to level I and II nodes (McMasters et al 1998, Rosen et al 1983, Veronesi et al
1987). The main site for “skip-metastasis” is level II (Blichert-Toft, 2000).
When ALND is used as a staging procedure, extra-axillary nodal involvement
remains unknown. Routine excision of IMN is not considered worthwhile, be-
cause of the low incidence of involved nodes and increased risk for morbidity
(Krag 2003).
5. Axillary lymph node sampling
The axillary lymph node sampling procedure includes random or palpation-di-
rected biopsy of the lower axillary lymph nodes (Forrest et al 1995). The theory
is based on the impression that every intraoperatively palpable tumor contains
metastases (Forrest et al 1995). Loco-regional control has been equal to both
four-node sampling and ALND (Forrest et al 1995, Chetty et al 2002). Intraop-
erative axillary node sampling in combination with SNB may reduce the false-
negative rate from 14% to 4% in tumors under 3 cm in diameter (Hoar and
Stonelake 2003). When only SN is involved, however, combining these proce-
dures is not recommended (Hoar and Stonelake 2003).
The position of this procedure in diagnosis of lymph node status is controver-
sial, because several authors consider the sampling procedure as a method equal
to clinical examination and thus inadequate in breast cancer staging (Steele et al
1985, Kissin et al 1982, Davies et al 1980). According to the Kissin and Davies
reports, axillary sampling failed to yield positive nodes in up to 24% of the pa-
tients (Kissin et al 1982, Davies et al 1980). However, sampling like SNB is
associated with decreased morbidity such as lymph edema (Rampaul et al 2003,
Forrest et al 1995).
6. Lymphatic mapping and sentinel node biopsy
6.1 History
Urologist Ramon Cabañas originally described the SN concept and usage of lym-
phangiograms in 1977 in surgery for penile cancer. He confirmed that the pro-
gression of the tumor cells into the lymphatic system is an orderly process, and
the first node to contain the metastasis shall be called an SN (Cabañas 1977). The
method of Cabañas did not achieve wide acceptance, due to the arbitrary locali-
zation method for SNs. Morton et al (1992) reported on cutaneous LS in iden-
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tifying lymph nodes in melanoma, hypothesizing that identification of lymph
drainage pathways from the primary tumor might indicate the site of the metas-
tases. Lymphatic mapping was developed for localization of these nodes, with
vital blue dye to stain the lymphatics. Krag et al introduced in 1993 radiolabelled
colloids and a gamma probe for identification of SNs in breast cancer. They were
able to identify SNs in 82% of the patients (Krag et al 1993). Giuliano et al
(1994) described first the intraoperative vital blue dye mapping in breast cancer
that achieved a 65% success rate. Albertini et al (1996) combined both tech-
niques with a 92% success rate (Figure 1).
The sentinel node biopsy technique was developed as a diagnostic test to
determine the status of regional lymph nodes. It is considered a minimally inva-
sive procedure, providing the same information as ALND with less morbidity. A
standardized technique for SNB is, however, thus far lacking.
As yet no results exist from long-term randomized trials comparing outcomes
after SNB and ALND (Krag et al 2003), but SNB has become a widely accepted
technique for axillary staging in breast cancer patients. SNB is usually applied in
breast cancer patients with tumors that are clinically node-negative, unicentric,
and at stage T1 to T2. In addition to SNs in the axilla, LS visualises SNs outside
the axilla in up to 34% of patients (Nieweg and Bartelink 2004).
Figure 1: Progression of lymph flow from a primary tumor to sentinel node and afterwards
to the second- and third-echelon nodes or two different sentinel nodes (SN)
(Nieweg 2001 c, permission of Lippincott Williams & Wilkins)
6.2 Methods
Methods for SNB vary in regards to performing the LS and harvesting the lymph
nodes (Borgstein et al 1998, Paganelli et al 1998, Glass et al 1999, Nieweg et al
1999, Uren et al 2001, Valdés-Olmos et al 2000, McMasters et al 2001a, Krag et
al 2003). The most variable parts of the method are the dosage, volume, and
particle size of the radioactive tracer, the site of the injection, and the use of
scintigraphy with or without blue dye.
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Preoperative LS is performed in order to identify the draining LN basins and
the number of SNs in the basin (Jansen et al 1998, Nieweg et al 1999). The flow
of radioactive colloid simulates the pathway of lymphatic spread and allows an
accurate prediction of nodes possibly involved (Kapteijn et al 1998).
Nodal uptake and the retention of the tracer depend on particle size and the
volume of the injection (Nieweg et al 1999, Valdés Olmos et al 2001, Leidenius
et al 2004). Accumulation of the tracer in a node depends also on the condition
of the lymphatic channels entering from the primary tumor to an SN and the rate
of the lymph flow (Nieweg et al 2001b).
The ideal tracer is drained swiftly to an SN and retained in the first draining
node without overflow to the secondary, second-echelon, nodes. A small parti-
cle-size agent accumulates fast and drains very quickly via the SN to the second-
echelon nodes and can easily lead to visualization and harvesting of the second-
echelon node (Nieweg et al 1999, Glass et al 1999). A large particle-size tracer
remains at the injection site and may diminish the visualization of the non-SNs
(Paganelli et al 1998, DeCicco et al 1998, Noguchi 2002).
Different radiocolloids are used for lymphatic mapping, but we still lack the
ideal one (Leppänen et al 2002, Leidenius et al 2004). The most widely used
radiopharmaceuticals are 99mTc- and isosulfran technetium and 99mTc-human col-
loidal albumin (Krag et al 1993, Giuliano et al 1994, Veronesi et al 1997, Glass
et al 1999). Administration of blue dye helps in the identification of blue-stained
lymph channels and their origin from the primary tumor (Miltenburg et al 1999).
The tracer may be injected intraparenchymally – intra- or peritumorally – or
superficially – sub- or intradermally into the overlying skin at the tumor site or
into the subareolar lymphatic plexus. The idea of the superficial technique is that
the overlying skin has the same embryologic origin as the breast parenchyma and
should share the same lymphatic drainage patterns (Borgstein et al 1997). Borg-
stein proposed that both peritumoral tracer injection and intradermal injection
drain to the same lymph node in the axilla (Borgstein et al 1997, 2000). The
advantage of the superficial injection technique is the excellent visualization rate
of SNs in LS, because of richer lymphatic drainage of the skin than of the breast
parenchyma (McMasters et al 2001a, Mateos et al 2001).
On the other hand, it has been proposed that the tracer injection should be
adjacent to the tumor; otherwise the risk is that a watershed of lymphatics is
crossed, and the visualized node will be draining another area of the breast and
not the tumor site (Canavese et al 2000, Valdés Olmos et al 2000). Drainage
patterns from the skin may be different from those of the underlying parenchy-
ma, because the SN in the internal mammary chain is seldom visualized follow-
ing an intradermal injection of the tracer (Roumen et al 1997). Deep injection
into or around the tumor is suggested to lead to absorption of the tracer into the
same lymph channel as the one that the cancer cells enter (Nieweg et al 1999,
Nathanson et al 2001) (Table 5).
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Table 5: Visualization and identification rates for sentinel nodes (SN) by differ-
ent lymphatic mapping techniques
                  Visualization         Identification
                         in LS             rate of axillary
No. Injection                (%) SN
Author of technique and
Pts dose of tracer Axilla Outside (%)
axilla
Krag 1998 443 PT (37 MBq) – 8 93
van der Ent 1999 70 PT(370MBq) 97 34 100
Rahusen 2000 115 PT (40–80MBq) 91 17 92
Jansen 2000 113 IT (40–60MBq) – 19 88
Valdés Olmos 2000 100 IT (42–88MBq) 96 19 90
Valdés Olmos 2000 50 IT (68–124MBq) 96 17 98
Doting 2000 141 IT (40–60MBq) 87 18 93
Van der Ent 2001 256 PT (370MBq) 95 25 97
Uren 2001 159 PT (5–10MBq) 93 8 96
Galimberti 2002 182 PT/SF 92 8 99
IT= intratumoral, PT= peritumoral, SF=superficial
6.3 Accuracy
Before any technique can be accepted as a reliable, clinically useful, and valid
diagnostic test, it should be sufficiently sensitive and specific. Overall accuracy is
estimated by false-negative and false-positive rates, in addition to positive and
negative predictive values. The crucial factor concerning the validity of the meth-
od is the false-negative rate, because any false-negative result could lead to under-
staging and undertreatment. Furthermore, the false-negative and -positive rates
of the procedure should be acceptable before the method can become the gold
standard (McMasters et al 1998).
An SN is defined as a lymph node receiving direct drainage from the primary
tumor (Morton et al 1992). It is considered to be the closest node to a primary
tumor or to be the first node visible in lymphoscintigraphy images. This, howev-
er, is true only if it actually is the first to receive direct drainage from the injection
site (Nieweg et al 2001c). The first visible node is therefore not always an SN,
because of preferential flow to the other nodes when the SN is occluded. It is
noteworthy that more than one SN can exist in the LS, when two or more lym-
phatic channels originate from the primary tumor.
The accurate performance of SNB requires a pilot study phase for the surgeon
(Cox et al 2001, Nieweg et al 2001b, McMasters et al 2001, Tanis et al 2002). In
the initial studies, most surgeons were able to identify the SN in over 90% of the
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patients. In these studies, a confirmative ALND was performed. The false-nega-
tive rate of SNB, that is, the proportion of patients with a negative SN with
subsequently proven axillary metastases has ranged from 0 to 29% of all node-
positive patients (Alex and Krag 1996, Albertini et al 1996, Giuliano et al 1997,
Borgstein et al 1997, Krag et al 1998, Miltenburg et al 1999, Fentiman and
Mansel 2002). The false-negative rate is the most important parameter in the
learning phase of SNB, not forgetting the identification rate. Reliable perform-
ance and quality of SNB requires in the learning phase a sufficient number of
involved SNs, which is, according Tanis et al, 150 procedures with 60 involved
nodes (Tanis et al 2002). Identification rate for SNs correlates with a decreasing
false-negative rate and the experience of the surgeon in performing the SNB
(Giuliano et al 1994, Giuliano et al 1997). Profound knowledge of the nuances
of the procedure facilitates the performance (Nieweg et al 1999), even more than
does the frequency of performances (McMasters et al 1998, Nieweg et al 1999,
Tanis et al 2002) (Table 6).
In addition, a successful and accurate performance of SNB requires close co-
operation between surgeon, nuclear medicine physician, and pathologist. The
accuracy of the SN procedure is based on lymphoscintigraphy and on biopsy of
the real SN and its meticulous histological examination (Canavese et al 2000,
Tanis et al 2002).
Table 6: Success, accuracy, and false-negative rate by percentage for different lym-
phoscintigraphy techniques for performing sentinel biopsy
No of Technique of Success Accuracy False
Author Year patients injection (%) (%) negative
(%)
Giuliano 1994 174 VD 66 96 11
Giuliano 1997 107 VD 94 100 0
Veronesi 1997 163 SD 98 98 5
Alex 1996 70 PT 71 100 0
Albertini 1996 62 PT 92 100 0
Krag 1998 443 PT 91 96 11
Rahusen 2000 115 PT 92 87? 37
Borgstein 1997 25 ID 100 100 0
Borgstein 1998 130 PT 94 98 2
ID= intradermal, PT= peritumoral, SD= subdermal
VD= vital blue dye
Accuracy= true positive + true negative/total number of patients
False negative: false negative/false negative+ true positive
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7. Sentinel node biopsy and cost impacts
SNB has currently been introduced into many breast surgery centers as an alterna-
tive to ALND for axillary staging in breast cancer. The method is less invasive and
provides a benefit for postoperative recovery and also probably for long-time
morbidity (Schrenk et al 2000, Burak et al 2002, Sener et al 2001, Leidenius et al
2003a, Haid et al 2002, Miguel et al 2001). SNB is expected to be a cost-effec-
tive procedure, although only a few studies cover this topic (Gemignani et al
2000, Chirikos et al 2001, Fenaroli et al 2004).
Estimation of total costs of a procedure is far from simple. Charges for a
procedure include both indirect and direct costs of illness (Leivo 2001). Hospital
charges usually include hospital-related costs like medication, laboratory tests,
lymphoscintigraphy, costs in the operating room including anesthesia, hospital
stay, and pathological examination of the primary tumor and the lymph nodes
(Gemignani et al 2000). As regards hospital charges, SNB has one weak link,
namely the intraoperative diagnosis, especially the false-negative rate involved
(Gemignani et al 2000).
As a consequence of the time-consuming extra workload in a pathology labo-
ratory, the intraoperative analysis of SNs increases charges. On the other hand,
overall charges may decline, because SNB enables breast surgery, axillary staging,
and treatment during the same procedure for the majority of patients (Gemigna-
ni et al 2000, Weiser et al 2000, Leidenius et al 2004). SNB does not significantly
raise hospital-related charges in stage ™ breast cancer, while only a few patients at
that stage need ALND as a second operation (Gemignani et al 2000). Further-
more, from the economic point of view, for T1 tumors, the frozen section anal-
ysis of SNs may not be worthwhile, because lymph node involvement in this
group is rare (Weiser et al 2000, Fenaroli et al 2004).
8. Sentinel node biopsy and surgery of nonpalpable
breast cancer
The proportion of nonpalpable breast lesions has increased during recent years
due to widespread use of mammographic screening and early diagnosis of breast
cancer (McLelland 1991, Luini et al 1999, Harlow et al 1999, Gray et al 2001,
Paganelli et al 2002). The most important factor in surgery for non-palpable
lesion is exact localization and the excision of the tumor with adequate margins
(Feggi et al 2001).
Localization of nonpalpable tumors is most commonly done by a stereotacti-
cally placed guide wire (Gray et al 2001). This method has many disadvantages;
the insertion of the wire is uncomfortable for the patient, displacement of a wire
occurs easily, and transsection of a wire is possible. Nonpalpable tumors are also
possible to localize by intraoperative ultrasound (Rissanen et al 1994, Rahusen et
al 1999, Harlow et al 1999)
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The nonpalpable tumors can be localized by injection of a radioactive seed
into a tumor with ultrasonic (US) or mammography guidance (Gray et al, 2001).
Accordingly, Gray et al (2001) found this method to be as feasible in localization
and retrieval of a nonpalpable lesion as the standard wire-guided method. Fur-
thermore, with their seed localization method, they observed reduced incidence
of histologically involved margins.
A method called radioguided occult lesion localization (ROLL) has been used
for the localization of non-palpable tumors since 1999 (Zurrida et al 1998, Feg-
gi et al 2001). Different techniques and combinations of radiopharmaceuticals
compounded with a colloid have been used in intratumoral and often also super-
ficial tracer administration (Zurrida et al 1998, Luini et al 1999, Gennari et al
2000, Feggi et al 2001, Tanis et al 2001, Barros et al 2002). After a single
intratumoral tracer injection, performance of simultaneous LS, SNB, and ROLL
is possible (Feggi et al 2001) (Table 7).
Table 7: Success rates in localization of nonpalpable lesions, visualization of sen-
tinel nodes in lymphoscintigraphy, and radicality of excision by radioguided oc-
cult lesion localization
Author Patients/ Localized Surgery Visualized Visualized
Injection  lesions sufficiently sentinel extra-
radical   nodes axillary
sentinel
nodes
(%) (%) (%) (%)
Luini et al,
1999 331 /IT 100 99.1 – –
Gennari et al,
2000 647 /IT 99 99.5 – –
Feggi et al,
2001 73/IT + SF 100 94.5 97.3 15.0
Tanis et al,
2001 56/ IT 100 92.3 93.0 43.0
Gallegos Hernandez
et al, 2004 65/ IT 100 83.0 – –
IT=intratumorally, SF = superficially
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9. Sentinel node biopsy and morbidity after breast
cancer surgery
The breakthrough of breast conserving therapy (BCT) with improved survival
has shifted the focus to postoperative morbidity after breast cancer surgery. Even
though these symptoms are not life threatening, they occur over a prolonged
period postoperatively and reduce significantly the quality of life in some breast
cancer patients (Voogd et al 2003, Bland & Copeland 2004).
A common and well-known postoperative complication after ALND is mor-
bidity of the upper extremity (Petrek et al 1990, Pezner et al 1986) including
lymphedema of the breast and upper extremity, as well as sensory and functional
disorders like numbness and motion restriction of the upper arm. These symp-
toms manifest among 20% to 80% women who have undergone AC and radio-
therapy (RT), (Tasmuth et al 1996, Recht et al 2001, Ververs et al 2001, Gos-
selink et al 2003, Yap et al 2003).  Risk for breast and upper arm lymphedema
seems to be higher after extensive axillary surgery (Clarke et al 1982, McCormick
et al 1989, Senofsky 1991, Temple et al 2002) and postoperative RT (Clarke et al
1982, McCormick et al 1989, Senofsky 1991, Isaksson and Feuk 2000). Most of
these symptoms manifest immediately or up to one year after surgery, but symp-
toms can appear until 2 to 5 years after ALND (Warmuth et al 1998).
A decreased risk was expected for early and long-time morbidity after the in-
troduction of SNB without further axillary treatment. The first studies have re-
ported significantly less arm morbidity after SNB than after AC (Schrenk et al
2000, Miguel et al 2001, Sener et al 2001, Burak et al 2002, Ernst et al 2002,
Haid et al 2002, Temple et al 2002, Blanchard et al 2003, Gosselink et al 2003,
Leidenius et al 2003 a, Peintinger et al 2003, Schijven et al 2003). Furthermore,
immediate postoperative recovery is faster after sole SNB than after AC (Burak
et al 2002, Leidenius et al 2003, Peintinger et al 2003). SNB without further
axillary treatment has, however, also been associated with postoperative morbid-
ity in these studies, but the clinical significance of any SNB-related morbidity is
still obscure.
9.1 Lymphedema
Lymphedema is an accumulative process, due to an imbalance between capillary
filtration and lymph drainage (Mortimer et al 1998, Zippel et al 2003). In breast
cancer, the disturbance of this balance occurs by interruption of the axillary lym-
phatic system by surgery or RT, leading to dysfunction, increased pressure, valve
dysfunction in lymphatic vessels, and dermal back flow, as well as accumulation of
protein-rich fluid in subcutaneous tissue (Mortimer 1998, Erickson et al 2001).
Edema may develop immediately after surgery or in a later postoperative phase
(Recht et al 2001).
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9.2 Upper arm lymphedema
Postoperative lymphedema in the upper extremity is the most well-known and
feared complication after breast cancer surgery. Incidence of cancer treatment-
related lymphedema in the upper arm may vary from 27% to 45% during the first
postoperative year, depending on operative technique – mastectomy or resection
(Tasmuth et al 1996). Tasmuth et al (1996) also revealed that upper arm edema
is more often detected than self-reported. The risk for upper arm edema is mini-
mal if the axilla is neither dissected nor irradiated, whereas the risk may increase
up to 27%, when one or the other treatment modality is added (Senofsky et al
1991, Meek 1998). Immediate or late postoperative arm edema occurs in 10 to
56% of patients who have undergone ALND (Gerber et al 1998, Schrenk et al
2000, Duff et al 2001, Sener et al 2001,Golshan et al 2003, Voogd et al 2003).
Combination of axillary RT and ALND increases the risk and incidence of upper
arm edema (Erickson et al 2001, Yap et al 2003). The other contributory factors
for lymphedema with surgery and irradiation are advanced stage at diagnosis,
obesity, and older age (Pezner et al 1986, Meek et al 1998, Deutsch and Flick-
inger 2003).
Objective measurement of lymphedema is difficult. A water displacement tech-
nique was used in initial measurements of arm lymphedema (Engler and Sweat
1962, Stranden et al 1981), and an optioelectronic volumetry and dielectric
method (Nuutinen et al 1998, Duff et al 2001). The most common method is
measurement of the arm circumference and comparison of results between the
operated and non-operated sites.
9.3 Breast lymphedema
Breast lymphedema is considered a minor problem among postoperative compli-
cations; perhaps one reason that it has not been studied extensively (Clarke et al
1982, McCormick et al 1989, Senofsky et al 1991). Mild symptoms may lead to
a most feared complication called delayed breast cellulitis, with an estimated inci-
dence of 3% to 5% (Zippel et al 2003). This may be difficult to distinguish from
an infection or underlying neoplastic process (Zippel et al 2003). Diagnosis of
breast lymphedema is complicated, due to lack of standardized measuring and
reporting criteria (Petrek et al 1996). Diagnosis is often a combination of clinical
findings and patients’ complaints (Clarke et al 1982, Rockson et al 1998).
The incidence of breast edema is associated with the extent of axillary surgery
and postoperative RT (Clarke et al 1982, Senofsky et al 1991). It ranges accord-
ing to different publications from 5% to 24% with limited axillary dissection up
to 15% to 80% when a full ALND is performed (Clarke et al 1982, Senofsky et al
1991, Meek 1998). A minimal risk (6%) for breast edema is reported in patients
with breast resection without RT (Senofsky et al 1991, Recht and Houlihan
1995).
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9.4 Functional disorders of the upper extremity
Postoperative functional disorders in breast cancer patients are associated with
extent of axillary treatment (Erickson et al 2001, Ernst et al 2002) and axillary
RT (Sugden et al 1998, Gosselink et al 2003). Furthermore, the type of breast
operation – mastectomy or resection – can influence shoulder motion. Upper
arm morbidity and motion restriction manifests more often after mastectomy
than after BCT (Sugden et al 1998, Ernst et al 2002, Gosselink et al 2003),
usually immediately after surgery and during the following 6 postoperative months
(Duff et al 2001). Motion restriction is associated with ALND and postoperative
RT, appearing in 73% of patients with RT and in 35% of patients without (Sug-
den et al 1998, Gosselink et al 2003).
9.5 Sensory disorders of the upper extremity
Results of most studies of sensory disorders are based on the patient’s self-experi-
ence, using either a validated or non-validated questionnaire as the measuring
instrument (Tasmuth et al 1996, Warmuth et al 1998, Schrenk et al 2001, Burak
et al 2002, Temple et al 2002). In most studies, sensory disorders are described
by the terms numbness, tenderness, or pain (Schrenk et al 2001, Burak et al
2002, Haid et al 2002).
Sensory disorders like numbness most often manifest immediately after sur-
gery and improve significantly during the first 3 months after surgery (Temple et
al 2002). Prolonged, mild sensory changes have been evident even 5 years after
ALND in 55% to 72% of patients (Warmuth et al 1998, Haid et al 2002).
Postmastectomy pain syndrome is also related to breast cancer treatment, af-
fecting 30% to 60% of the patients (Tasmuth et al 2003). The etiology of this
syndrome is supposed to be injury of the intercostobrachial nerve or brachial
plexus, or both (Freeman et al 2003). It is disabling, affecting daily- life function
of the upper arm (Tasmuth et al 2003). According to Miguel and co-workers’
study (2001), referrals to their pain clinic decreased between 1991 and 1998,
suggesting that the increasing number of SNBs have reduced the incidence of
surgery-related pain syndrome.
Pain often presents in combination with other sensory disorders like numb-
ness. Preservation of the intercostobrachial nerve may prevent sensory deficit and
reduce long-term symptoms after AC (Freeman et al 2003).
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Hypothesis of the Study
1. SNB facilitates nodal staging in breast cancer.
2. Postoperative morbidity after SNB is minimal.
3. Simultaneous lymphatic mapping and SNB can be combined into a simple
localization method for nonpalpable breast tumors.
4. In breast cancer staging, SNB is thus a cost-effective method.
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Patients and methods
The study was carried out at the Breast Surgery Unit of Helsinki University Hospi-
tal between 30 May 2000 and 28 February 2002. The study included 426 consec-
utive breast cancer patients with clinical T1-T2 stage axillary node-negative cancer
undergoing SNB during the study period. In addition, 22 breast cancer patients
undergoing diagnostic ALND were included (Study IV) (Table 1).
Table 1: Number of study patients and exclusion criteria
No Name of Number of Number in Number Exclusion
study  patients  groups excluded  criteria
I Sentinel
nodes
outside 170 – – None
level I–II of
axilla
II Radioguided ROLL 64 Prior excisional





237 – – None
costs
IV Breast SNB 57
lymphedema 160 AC– 57 – None
after BCT AC+ 46
V One year SNB 43 Preoperative
morbidity 109 AC 40 26  examination
after SNB impossible
scheduling
AC– = patients in axillary clearance group, uninvolved nodes
AC+ = patients in axillary clearance group, involved nodes
AC = patients with axillary clearance
PALP =patients with palpable tumor
ROLL = patients with radioguided occult lesion localization
SNB = sentinel node biopsy
WGR = patients with wire-guided resection
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Lymphoscintigraphy
Lymphoscintigraphy was performed the day before surgery, 4 hours after an in-
tratumoral injection of 80 to 100 MBq 99m Tc-labeled human albumin colloid
Nanocoll®  (particle size <80 nm: Nanocoll®, Sorin Biomedica diagnostics, Salug-
gia, Italy) or Albu-Res® (particle size 200-3000 nm, ALBU-RES® 99m Tc albu-
min microcolloid, Nycomed Amersham Sorin s.r.l.) in a volume of 0.2 ml.
The radioactive tracer was injected intratumorally under palpation control by
a nuclear medicine physician when the tumor was palpable. In cases with nonpal-
pable tumor, the tracer was injected under US control or by use of a stereotacti-
cally placed guide wire. In patients with nonpalpable tumors (Study II) the sin-
gle intratumoral injection of the radioactive tracer for LS was the only tumor-
localization method and was used also for localization of the SN.
Anterior and lateral planar views were obtained with a gamma camera. Esti-
mated locations of sentinel nodes were marked on the skin with a permanent pen
for both projections.
Sentinel node biopsy
At least 5 minutes prior to incision, 1 ml of Patent Blue dye was injected intratu-
morally (Bleu Patenté V; Laboratoire Geuerbet, Aulnay-sous-Bois, France). The
SNs were harvested with a hand-held gamma probe (Neoprobe 2000, Johnson &
Johnson Medical, Hamburg, Germany or Navigator GPS, Auto Suture European
Services Center, S.A., France) and by searching for blue-stained lymphatic vessels
and nodes. SNs in the axilla were sought on all occasions, and when clearly visible
in LS, attempts were made to retrieve them. AC was performed when the SNs in
the axilla were involved, were not identified, were blue only – without any radio-
activity, or if the tumor proved to be multifocal.
Breast surgery
In all patients with breast conserving surgery (BCT), a wide local excision of the
tumor was performed aiming at 1- to 2- cm free margins and including the
underlying pectoral fascia and most often a slice of overlying skin (Aspegren et al
1988). In Study II, the nonpalpable tumors visible in US (ROLL group) were
excised guided by a gamma detector searching for the area of maximal radioactiv-
ity, which showed the center of the tumor, or excised with the guidance of a
stereotactically placed guide wire (WGR group). In a case of a nonpalpable tu-
mor, a specimen X-ray ensured radiological free margins.
During primary surgery, if the tumor proved not to be suitable for BCT because
of multifocality or larger size than evaluated preoperatively, the operation was con-
verted to mastectomy. Tumor multifocality was confirmed by intraoperative frozen
section diagnosis, and permission for conversion had been obtained preoperatively.
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When the margins were involved or close (< 3 mm), in agreement with the patient,
a second operation was performed, either mastectomy or re-resection.
Adjuvant therapy
Patients with BCS received postoperative RT to the breast area, in addition to the
axillary, supraclavicular, and internal mammary fields, if axillary nodes were in-
volved. The patients received adjuvant chemotherapy and hormonal therapy ac-
cording to the guidelines of the Department of Oncology, Helsinki University
Central Hospital (Tables 2 and 3).
Table 2: Adjuvant treatment of 160 breast cancer patients with sole SNB or with
AC with uninvolved or with involved nodes (Study IV)
Adjuvant SNB Patients with Patients with
treatment AC and tumor- AC and tumor-
negative nodes positive nodes
N=57 N=57 N=46
Radiotherapy 55 (96%) 56 (98%) 46 (100%)
Chemotherapy 8 (14%) 7 (12%) 20 (57%)
AC= axillary clearance
SNB= sentinel node biopsy
Table 3: Axillary nodal status, breast surgery, and adjuvant therapy for the 83




None 7(16%) 1 (3%)
Breast only 35 (82%) 5 (14%)
Breast, axillary, and supraclavicular fields 1 (2%) 34 (83%)
Adjuvant systemic therapy
None 22 (51%) 3 (7%)
Cytotoxic treatment 3 (7%) 2 (5%)
Tamoxifen 15 (35%) 11 (28%)
Cytotoxic treatment and Tamoxifen 3 (7%) 24 (60%)
Breast operation
Resection 35 (81%) 28 (70%)
Mastectomy 8 (19%) 12 (30%)
Axillary nodal status
N1 1 (2%) 33 (82%)
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Histological methods
Sentinel lymph nodes (Studies I–IV)
SNs were sent to the pathology laboratory as separate samples labeled with their
sites of origin. The fresh specimens were cleaned of all extra capsular fat tissue,
measured, sliced into 1 to 1.5 mm thick sections, and mounted on iced OCT®.
Touch preparations and frozen sections from two levels were made from these
slices; these were then stained with toluidine blue and viewed. All remaining tissue
was fixed in phosphate-buffered 10% formalin and embedded in paraffin, and sec-
tions were stained with H&E and with Cam 5.2 immunostain. When no frozen
section diagnosis was required (sentinel nodes outside the axilla), the nodes were
fixed directly in phosphate-buffered 10% formalin. After fixation, the nodes were
cleaned of fat, cut, and totally embedded. H&E sections were made from two levels
of each lymph node, and cytokeratin immunostaining was done from level 1.
Breast specimens (Study II)
All resected specimens were sent to the pathology laboratory, pinned on a styrox
board with a sketch of the appropriate breast. In cases of nonpalpable tumors,
the radiographic edges of the tumors were marked with needles placed in connec-
tion with a specimen X-ray. The specimen was painted with commercial vital dyes
(WAK-CHEMIE MEDICAL GMBH, Bad Soden, Germany), always in the same
fashion, yellow on the anterior surface of the palpable tumor and between the
marking needles in the specimens with nonpalpable tumors. The medial margin
of the specimen was marked red, the lateral green, the cranial black, and the fascia
blue. The specimen was detached from the styrox board, weighed, and cut fron-
tally. If no tumor was visible in either of the two sections, they were cut frontally
once more, and so on, yielding less than 1-cm-thick slices. These slices were kept
on bits of paper and numbered. The greatest diameter and the distance to the
lateral margins were measured with a ruler for all tumors observed in the speci-
men. After 1- to 2- days’ fixation in 10% formalin, representative areas were se-
lected for histological examination. These included one center section contain-
ing the tumor at its greatest diameter in gross examination, and at least the
closest lateral margin (most often all the lateral margins), as well as crosswise
sections from the bottom and the surface containing the anterior and posterior
margins. During the microscopic examination, the tumor margins were ink-marked
on the slides; the vital dye marks were often reinforced on the glass with ink. All
margins were re-measured from the histological sections.
When, during the primary operation or afterwards, the resected specimen,
proved to be multifocal, the closest free margin of the resected specimen was
determined based on tumor closest to the edge of the specimen, irrespective of
whether it was the index tumor diagnosed preoperatively or an additional focus
detected during the primary operation or in the definite histology.
30 PATIENTS AND METHODS
In order to estimate whether the tumor had been excised without excessive
mass of healthy tissue, we related the size of the specimen to the histological
tumor size; the tumor-specimen ratio was evaluated by subtracting the histolog-
ical tumor size (the greatest dimension) from the maximum length and width of
the specimen. This tumor-specimen ratio was calculated by use of the histologi-
cal size of the index tumor diagnosed preoperatively also in cases with a multifo-
cal carcinoma.
Hospital costs (Study III)
The sequence of the staging and treatment procedures was registered for 237
consecutive patients (Study III). Axillary staging for the 237 patients was per-
formed by SNB with intraoperative frozen section diagnosis of SN metastases. In
addition, three hypothetical alternative treatment protocols were developed for
each of the 237 patients: diagnostic ALND, SNB as day-case surgery prior to the
breast operation, or SNB without frozen-section diagnosis. Thereafter, the hypo-
thetical sequence of the staging and treatment procedures for each patient was
estimated, first, application of diagnostic ALND for axillary staging, second, if
SNB as day-case surgery prior to the breast operation had been applied, and
third, application of SNB without frozen section diagnosis. Hospital costs were
calculated based on the real or hypothetical sequences of surgical staging and
treatment procedures for each axillary staging alternative.
For calculation of costs, we used unit costs based on the detailed internal
accounting system of the Helsinki University Hospital. These were estimated
according to the production costs of the various services and procedures in 2001.
The costing included hospital inpatient care, outpatient visits, LS, surgery, and
pathological analysis. The cost of hospital inpatient care comprises room and
board, medication, blood products, and laboratory costs, as well as pre- and
postoperative nursing care. The cost of an outpatient visit comprises pre- and
postoperative check-ups. The cost of pathology analysis includes intra-operative
frozen section diagnosis of SNs, and postoperative histological examinations of
SNs and breast specimens, as well as the ALND specimens in patients with AC.
The costs of surgery comprise all costs arising from the operation including an-
esthesia and the recovery room.
Patients were admitted to the hospital on the day before surgery. On average,
they were discharged on the first day after breast surgery and SNB and on the
second day after AC. These patients left with a drainage tube, which was removed
as an outpatient procedure on the fifth day after surgery.
Clinical breast examination (Study IV)
Clinical examination of the operated and the contralateral breast was performed a
median of 12.6 (11.3–18.8) months after the operation by specialist surgeons or
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surgical residents. Data were collected from case report forms (CRFs). The size,
edema, tenderness, and pigmentation of the breast and the condition of the skin
in the scar area and in the whole breast were recorded.
Radiological methods (Study IV)
In order to evaluate the breast edema, an experienced breast radiologist performed
US on the breasts after the clinical follow-up visit blind to the exact surgical
procedure performed. Patients from remote residential areas were excluded from
the extra US examination. The US examinations were performed with a real-time
US unit having a linear probe of 5 to 13 MHz focused upon the area of interest.
The total skin thickness of the four quadrants of the breasts was recorded both
for the operated breast and the contralateral breast, as was the presence of any
interstitial edema and fluid collection.
The thickness of the breast skin varies between 1 and 2 mm, with a mean
thickness of 1.7 mm (Nuutinen et al 1998). The skin complex is comprised of
two thin echogenic lines with a hypoechoic dermis between them (Mendelson
1992).
Thickening of the skin of over 2 mm with increased echogenicity, distur-
bance, or poor visibility of the deeper echogenic line and interstitial fluid accu-
mulations were considered edema. Both interstitial fluid and fluid accumulation
is considered as varying degrees of lymphedema, and in this study both were
registered as lymphedema.
Clinical arm examination (Study V)
The range of shoulder motion, circumference of the upper extremity at six levels,
and skin sensation in the innervation area of the intercostobrachial nerve were
measured preoperatively, as well as at 2 weeks and 3, 6, and 12 months postoper-
atively.
Flexion, abduction, and external and internal rotation were measured by a
goniometer, with reasons for limited movement registered. A reduction of 10°
or more in the range of shoulder motion compared with the preoperative meas-
urement was considered as motion restriction.
The circumference of the upper extremity was measured with a tape measure
around the ring finger, the wrist, and 10 cm and 20 cm below the lateral epi-
condyle, as well as 10 cm and 20 cm above the lateral epicondyle.
For evaluating lymphedema, in each patient, the differences between  the pre-
and postoperative circumference were compared between the ipsi- and contralat-
eral upper extremities at each measurement point and expressed as percentages of
the preoperative circumference of the ipsilateral side by the formula:
(PoI-PreI) – (PoC-PreC)   × 100%
PreI
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where PoI is the postoperative and PreI the preoperative circumference of the
ipsilateral upper extremity, and PoC and PreC are the post- and preoperative
circumference of the contralateral arm, correspondingly. Increase in arm circum-
ference (LE%) was defined as the mean difference at the six measurement points.
Skin sensation was measured on the medial aspect of the upper arm, the axilla,
and the breast area with von Frey filament stimulation. Difference in skin sensa-
tion more than the thickness of one filament was considered impaired sensation.
Self-reported morbidity (Study V)
Self-experienced morbidity one year after surgery in regards to lymphedema and
sensory and functional disorders and their interference with daily life was evaluat-
ed by a questionnaire. Prevalence and intensity of symptoms such as pain, lymph-
edema, strange sensations, numbness, muscle weakness, frozen-shoulder-like symp-
toms, and shoulder stiffness were measured on a visual analogy scale (VAS), (10
cm scale, 0= no symptoms, 10 cm = worst possible). The VAS scale result in all
these symptoms was considered as follows: <20 mm mild, >20–40 mm moder-
ate, and >40 mm severe (Huskisson 1974, McQuay and moore 1998).
Statistical analysis
The significance of difference between the study groups was tested by the two-
tailed Fisher’s exact test (Studies I, II, IV, V). The medians were compared using
the non-parametric test, Mann-Whitney-U. Cross tabulations were used in com-
paring the groups, and differences were tested by the Chi Square- and Fisher’s
exact tests. P-values less than 0.05 in two-sided tests were considered statistically
significant.
The statistical analysis was performed by a computer system (SPSS, Inc., Chi-
cago IL, USA), (Studies IV–V). Calculations in the study concerning hospital
cost (Study III) were carried out by a computer-based decision tree model built
on DATA 3.5 (Tree Age Software Inc.).
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Results
Prevalence of SLN and SLN metastases outside level I–II
of the axilla
LS showed SNs in the axilla in 150 (88%) of the 170 cases and outside level I to
II of the axilla in 30 (17%) cases. SNs in the internal mammary basin were visual-
ized in 22 (13%) patients, and drainage solely outside the axilla was visible in two
(1%) patients. Lymphatic mapping failed to visualize SNs in 20 (12%) cases.
In 30 patients, a total of 55 SNs were visualized outside the axilla in the LS.
These included 38 internal mammary, 9 subclavicular, and 7 intramammary nodes,
and one interpectoral node.
Patients with SNs outside the axilla were somewhat younger, with a median
age of 51 years (range 26–81), than those were without such nodes, with their
median age of 57 (range 28–86) (p=0.02). No differences existed in BMI, later-
ality of the breast cancer, tumor size, grade, histology, and particle size of the
tracer, or in the rate of axillary metastases between cases with or without SNs
outside the axilla. Lymphatic drainage to SNs in the IMN occurred from both
mediocentral and lateral tumors (Table 4).
Table 4: Tumor location and incidence of sentinel nodes in internal mammary
basin, axillary metastases, and metastases in internal mammary sentinel nodes in
172 breast cancer cases (Study I)
Event Upper Lower Upper Lower Central
Lateral Lateral Medial Medial
(N=95) (N=26) (N=33) (N=7) (N=11)
Sentinel nodes in
internal mammary 10(11%) 7(2%) 2(9%) 2(29%) 1(5%)
basin
Axillary metastases 31(33%) 13(50%) 12(36%) 0 (0%) 3 (27%)
Metastases in internal
mammary basin 0 (0%) 2 (8%) 2 (7%) 0 (0%) 0 (0%)
The median number of harvested SNs in the axilla was 2 (1–15). Nodes identified
in the axilla were both blue and radioactive in 100 (58%) cases, only blue in 5
(3%) and only radioactive in 46 (27%). Neither blue nor radioactive nodes ap-
peared in the axilla in 21 (12%) patients.
SNs outside the axilla were successfully harvested in 27 of 30 (90%) of the
cases, with 43 (78%) retrieved of the 55 SNs visualized outside the axilla in the
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LS. The success rate in harvesting the SNs in the internal mammary chain was
86% (33 of 38).
An additional skin incision was necessary in 15 patients (79%) of those with
BCS and in none of those who underwent mastectomy during harvesting of the
SNs outside the axilla. A minimal perforation of the parietal pleura occurred in
three (10%) patients, who all recovered uneventfully without pleural drainage.
Axillary metastases were found in 59 (34%) of all 170 cases and in 12 (40%) of
the 30 cases with SNs outside the axilla. In the axilla, SNs were the only metastat-
ic nodes in 65% of the cases. Five patients (3% of all cases, 17% of those with SNs
outside the axilla) had metastases in the SNs outside the axilla, and two of these
five patients had no axillary metastases.
Radioguided surgery of nonpalpable tumor (Study II)
Localization of the tumor was successful in all the 215 cases, and excision of the
tumor was complete in 200 of 215 (93%) after the primary operation. Free mar-
gins of at least 10 mm were achieved in 166 of 215 (77%) in the primary opera-
tion without statistically significant differences between patient groups. The median
length of the closest margin was 15 mm (range 0–40 mm), without differences
between the ROLL, WGR, or palpation groups. The proportion of cases with
involved margins was highest in the WGR group (29%) as was excessively wide
margins (closest margin over 20 mm), 29% (Table 5).
Table 5: Median histological tumor size and free tissue margins after resection
with radioguided occult lesion location (ROLL), wire-guided resection (WGR),
or palpable tumors resection
Closest margin ROLL WGR Palpable tumors
N=64 N=14 N=137
Length (median, mm range,) 12 (0–35) 10 (0–30) 15 (0–40)
10 mm or more 44 (69%) 8 (57%) 114 (83%)
Involved * 3 (5%) 4 (29%) 8 (6%)
Close or involved (0–3 mm) # 5 (8%) 4 (29%) 9 (7%)
Excessively wide (>20 mm) 9 (14%) 4 (29%) 32 (23%)
* p= 0,03 between ROLL and WGR and between WGR and palpable tumors
# p<0,05 between WGR and palpable tumors
Median size of the resected specimen was 8 (SD±2.9) × 7 (SD±2.2) cm, with the
size largest in the WGR group, although median histological tumor size was
smallest.  However, the operation technique (resection with ROLL, WGR, or in
palpation did not influence significantly the tumor-specimen ratio (maximum
length of the specimen – histological tumor size or maximum width of the spec-
imen – histological tumor size, or both) (Table 6).
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Table 6: Median size of the resected specimen in centimeters, length and width
of the resected specimen subtracted from the tumor and the tumor-specimen
ratio after radioguided occult lesion location (ROLL), wire-guided resection
(WGR), or palpable tumors resection
ROLL Palpable tumors WGR
Size n=64 n=137 n=14
Length of specimen * 8.0 (4.5–15.0) 8.0 (1.8–25.0) 9.75 (7.5–25.0)
Length – tumor size 6.9 (1.9–13.9) 6.35 (0–22.6) 7.55 (2.6–23.0)
Width of specimen # 6.0 (3.3–14.0) 7.0 (1.5–13.0) 7.5 (6.8–20.0)
Width – tumor size 5.3 (0.9–12.9) 4.95 (0–10.6) 6.4 (0–18.0)
Median (range)
*p<0.01between ROLL and WGR and between palpable tumors and WGR
 #p< 0.05 between ROLL and WGR and between palpable tumors and WGR
An additional excision to ensure free tissue margins was performed on 52 of the
215 (24%) during the primary operation, based on palpation of the specimen
(palpable tumors) or on findings in the specimen X-ray (nonpalpable tumors).
An additional excision was performed equally often in all patient groups.  The
histological finding in the resected additional tissue was benign in 70%. None of
these 52 patients needed re-operations due to insufficient margins.
The operation was converted to mastectomy during the primary operation in
13 (6%) of all patients, a conversion was equally common in all patient groups.  A
second operation (mastectomy or re-excision) was considered necessary due to
multifocal carcinoma or close or involved margins in 17 (8%). The second oper-
ation was required most often in the WGR group. The overall mastectomy rate
during the primary or as a second operation was 11% (24 of 215), with no differ-
ence between patient groups (Table 7).
Table 7: Additional procedures during primary surgery or second operation in pa-
tients with palpable and nonpalpable tumors undergoing breast conserving surgery
Event Radioguided occult Wire-guided Palpable
lesion location (ROLL) resection (WGR) tumors (P)
N=64(%) N=14(%) N=137(%)
Extra excision during 14 (22) 4 (23) 34 (25)
primary operation
Re-operation * 7 (11) 3 (21) 5 (4)
Mastectomy during 5 (8) 1 (7) 7 (5)
primary operation
Mastectomy, total 10 (16) 3 (21) 11 (8)
*p = 0.05 between WGR and P
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The median histological tumor size was largest, 15 mm, for palpable tumors,
compared to 12 mm in the ROLL group or 9.5 mm in the WGR group (p
<0.001 between palpable tumors and WGR, p < 0.005 between ROLL and pal-
pable tumors). Ductal carcinoma in situ (DCIS) was encountered most often
(21%, 3 of 14) in the WGR group, compared to the ROLL group (4%, 4 of 64)
or in patients with palpable tumors (1%, 1 of 137, p<0.005 between WGR and
palpable tumors).
The histology of the resected specimen revealed multifocal carcinoma in 12%
(17 of 137) of patients with palpable and in 6% (5 of 78) with nonpalpable
tumors (NS). Multifocality seemed to be less common in the ROLL group (5%,
3of 64) than in the WGR group (14%, 2 of 14), but without a significant differ-
ence. The prevalence of an extensive intraductal component was highest (36%, 5
of 14) in the WGR group compared to the ROLL group’s 14% (9 of 64) or
compared to palpable tumors (7%, 9 of 137, p<0.01 between WGR and palpable
tumors).
SNB and impact on hospital costs
The hospital costs per patient with SNB and intraoperative frozen section diag-
nosis were 3750 €. Costs per patient would have been 3020 € in the ALND
model, 4087 € had the frozen section not been applied, and 4573 € in the “SNB
as day-case surgery” model. The most expensive axillary staging was thus one and
a half time times as expensive as the most economical.
The false-negative rate with the intraoperative frozen section diagnosis was
13% (9 of 68) of patients with tumor-positive SN. Based on the sensitivity analy-
sis, all economic advantage of intraoperative diagnosis would have been lost with
a false-negative rate of 35% or more. In other words, the costs with or without
frozen section diagnosis would be equal at a threshold false-negative rate of 35%.
Among these 237 patients, two operations were necessary for the treatment
and axillary staging of breast cancer in 19 (8%). More than one operation would
always have been necessary in the “ SNB day-case surgery” model (Table 8).
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Table 8: Treatment procedures in 237 breast cancer patients with sentinel node
biopsy (SNB) and intraoperative frozen-section diagnosis of sentinel node metas-
tases
Treatment                Patients
N %
Breast surgery
Breast conserving surgery 185 78
Mastectomy 50 21
Lumpectomy prior to SNB 2 1
Second operation
Mastectomy 8 4
Axillary clearance as second operation: false-negative
finding in frozen section 9 4
Axillary clearance as second operation: multifocal
carcinoma 5 2
Axillary surgery
SNB only during primary operation: negative finding in
frozen section 144 61
AC during primary operation: true-positive finding in
frozen section 59 25
AC during primary operation: false-positive finding in
frozen section 1 <1
AC during primary operation: SN unidentified 33 14
Postoperative breast lymphedema in clinical examination
(Study IV)
In the clinical examination the operated breast was more tumid than the contral-
ateral one in 34% (55 of 160) of the patients. Clinical breast edema was most
common, in 48% (22 of 46) of the patients with AC and involved axillary nodes,
and least common in 23% (13 of 57) with SNB only (p<0.05).
After RT, of the 160 patients, 37% had edematous or thickened skin (orange
peel), erythema, significant pigmentation, or other skin damage. In general, pig-
mentation of the skin in the operated breast was a common clinical finding, at a
prevalence of 59% (94 of 160), including also the slightest pigmentation. Ab-
normal tenderness during breast palpation was experienced by 46% (73 of 160).
The prevalence of these signs was not influenced by the extent of axillary surgery
(Table 9).
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Table 9: Findings in the clinical examination one year after breast-conserving
treatment and sole sentinel node biopsy (SNB) or axillary clearance (AC)
Breast finding SNB Patients with Patients with
AC and tumor- AC and tumor-
negative nodes positive nodes
N=57 N=57 N=46
Edema * 13 (23%) 20 (35%) 22 (48%)
Breast sizes
Equal 23 (40%) 21(37%) 23 (50%)
Smaller 26 (46%) 28 (49%) 20 (44%)
Larger 7 (12%) 8 (14%) 3 (6%)
Not applicable 1 (2%)
Pigmentation
None 28 (49%) 21 (37%) 16 (35%)
Slight 24 (42%) 24 (42%) 18 (39%)
Clear 5 (9%) 12 (21%) 11 (24%)
Not evaluated 1 (2%)
“Orange peel” skin 0 (0%) 4 (7%) 2 (5%)
Erythema 1 (2%) 2 (4%) 5 (12%)
Breast firm/compact 7 (12%) 10 (18%) 8 (17%)
Tenderness 21 (37%) 30 (53%) 22 (48%)
Scar area normal 47 (82%) 39 (68%) 38 (83%)
*p= 0.029
Postoperative breast lymphedema in ultrasound
examination (Study IV)
Thickness of the skin on the non-operated breast was constant in every segment
of the breast. On the operated side, thicker skin was evident more often in pa-
tients after AC than in patients with SNB only (p=0.01–0.001) (Table 10).
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Table 10: Median skin thickness on the breast measured by ultrasonography one
year after breast conserving treatment and sole sentinel node biopsy (SNB) or
axillary clearance (AC)
Localization of SNB Patients with Patients with
measurement AC and tumor- AC and tumor-




Upper lateral 1.1 (0.7–2.5) 1.1 (0.6–1.6) 1.0 (0.6–1.6)
Upper medial 1.2 (0.9–2.9) 1.2 (0.7–1.6) 1.3 (0.9–1.7)
Lower lateral 1.3 (0.7–2.1) 1.3 (0.8–1.9) 1.3 (0.8–1.9)
Lower medial 1.1 (0.7–2.2) 1.1 (0.7–1.7) 1.1 (0.7–1.6)
Operated breast
Breast Segment
Upper lateral * 1.5 (1.0–4.4) 1.9 (0.7–5.5) 1.8 (1.1–6.6)
Upper medial # 1.7 (0.9–4.6) 2.5 (1.2–6.5) 2.7 (0.9–6.1)
Lower lateral # 1.9 (0.9–5.5) 2.9 (1.4–64) 3.4 (1.1–7.5)




Subcutaneous edema in the operated breast was encountered after AC in 70% of the
patients and in 28% after SNB alone. Fluid collection in the operated breast was
more common in the AC group – in 56% – than after SNB only, 17% (Table 11).
Table 11: Prevalence of subcutaneous edema and interstitial fluid collections di-
agnosed by ultrasonography one year after breast conserving treatment and sole
sentinel node biopsy (SNB) or axillary clearance (AC)
Localization of SNB Patients with Patients with
measurement AC and tumor- AC and tumor-
negative nodes positive nodes
N=36 N=37 N=29
Subcutaneous edema * 10 (28%) 26 (70%) 20 (69%)
Interstitial fluid # 6 (17%) 20 (54%) 17 (59%)
*p<0.001 between SNB and AC groups, p<0.001 between SNB and AC with tumor-negative nodes and
p<0.001 between SNB and AC positive nodes 
#p<0.001 between SNB and AC groups, p=0.001 between SNB and AC with tumor-negative, p<0.001
between SNB and AC with tumor-positive lymph nodes
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Postoperative functional disorders (Study V)
In the preoperative measurement, the range of at least one of the ipsilateral shoulder
motions was restricted at least 10° from its anatomical range in 26 of the 83
(31%) patients. Of the 83 patients, 27  (33%) complained of strain in the pectoral
muscle during the preoperative evaluation. Such strain was also the most com-
mon reason for postoperative restricted shoulder motion, irrespective of axillary
treatment.
One year after surgery, four (10%) of the patients in the SNB group and nine
(22%) in the AC group had impaired flexion of the ipsilateral shoulder (p=ns). A
similar, non-significant difference in shoulder abduction occurred. Extent of ax-
illary treatment had no influence on internal and external rotation of the ipsilat-
eral shoulder. The range of shoulder motion of the contralateral shoulder re-
mained unchanged during follow-up (Table 12).
Table 12: Incidence of motion restriction in the ipsi- and contralateral shoulders
2 weeks and 3, 6, and 12 months after sole sentinel node biopsy (SNB) in 43
patients or after axillary clearance (AC) in 40 patients
Upper extremity function                          Follow-up
2 weeks 3 months 6 months 12 months
Flexion
Ipsilateral * SNB 16 (37%) 3 (7%) 4 (9%) 4 (10%)
AC 32 (78%) 1 (3%) 1 (3%) 9 (22%)
Contralateral SNB 1 (2%) 3 (7%) 3 (7%) 1 (2%)
AC 2 (5%) 0 (0%) 0 (0%) 0 (0%)
Abduction
Ipsilateral # SNB 19 (44%) 4 (10%) 3 (7%) 3 (7%)
AC 29 (73%) 3 (8%) 0 (0%) 6 (16%)
Contralateral SNB 2 (5%) 1 (2%) 3 (7%) 1 (3%)
AC 3 (7%) 0 (0%) 0 (0%) 1 (0%)
External rotation
Ipsilateral SNB 8 (19%) 2 (5%) 4 (9%) 6 (16%)
AC 7 (21%) 0 (0%) 0 (0%) 6 (16%)
Contralateral SNB 0 (100%) 0 (0%) 1 (2%) 4 (11%)
AC 1 (3%) 0 (0%) 0 (0%) 3 (8%)
Internal rotation
Ipsilateral SNB 1 (2%) 0 (0%) 1 (2%) 0 (0%)
AC 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Contralateral SNB 0 (0%) 0 (0%) 0 (0%) 0 (0%)
AC 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 *p<0.001 between SNB and AC 2 weeks after surgery
 #p<0.01 between SNB and AC 2 weeks after surgery
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Of the 43 SNB-group patients, 8 (19%) of complained of mild or moderate mus-
cular weakness in the ipsilateral arm one year after surgery, while patients in the AC
group more often reported muscle weakness (17 of 40, 42%, p<0.05). Shoulder
stiffness and tension neck-like symptoms seemed to bother patients slightly more
often in the AC group, but differences between the groups were non-significant.
Postoperative breast and upper extremity sensory
disorders (Study V)
Impaired skin sensation in the medial aspect of the ipsilateral upper arm, axilla,
and breast was more common after AC up to 6 months after surgery (p<0.001).
The impaired skin sensation improved in the AC group, and all differences be-
tween the groups disappeared during the last 6 follow-up months.
Self-reported numbness in the ipsilateral arm (p<0.001) and breast area
(p<0.01) were clearly more common after AC than after SNB alone. After more
extensive axillary treatment 3 SNB group patients reported only mild arm numb-
ness, whereas 14 patients complained of mild, three of moderate, and six of severe
arm numbness (p<0.001). Strange arm sensations were also more common, in
25 (62%) AC group patients compared to 8 (19%) SNB group patients (p=0.001).
Altogether 62 (75%) patients complained of at least some pain in the surgical
area or in the ipsilateral arm. Pain in the arm was more common in the AC group,
in 21 (52%) patients compared to 12 (28%) in the SNB group (p<0.05). Eight
(22%) AC-group patients complained of daily pain in the arm and the breast area,
while in the SNB group, four patients suffered daily pain in the breast (p=ns), and
two in the arm (p<0.01). Medication to relieve the pain was necessary in 12 to 20%
of the patients, but the difference between groups was non-significant (Table 13).
Table 13: Incidence of impaired sensation in 83 breast cancer patients 2 weeks
and 3, 6, and 12 months postoperatively after sentinel node biopsy (SNB) or
axillary clearance (AC)
Sensory area Time
2 weeks 3 months 6 months 12 months
Medial aspect of upper arm
SNB 1 (2%) 0 (0%) 0 (0%) 0 (0%)
AC 8 (24%) * 5 (15%)# 3 (10%) 0 (0%)
Axilla SNB 3 (7%) 0 (0%) 0 (0%) 1 (2%)
AC 16 (48%)# 14 (42%)# 10 (30%)∆ 1 (3%)
Breast SNB 2 (5%) 0 (0%) 0 (0%) 0 (0%)
AC 13 (39%)# 10 (32%)¤ 8 (24%)• 3 (9%)
*p<0.01 between SNB and AC groups 2 weeks after surgery
#p<0.001 between SNB and AC groups 2 weeks after surgery
¤p<0.001 between SNB and AC groups 3 months after surgery
∆p<0.001 between SNB and AC groups 6 months after surgery
•p<0.01 between SNB and AC groups 6 months after surgery
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Postoperative lymphedema (Study V)
None of the patients after SNB alone was referred to lymph therapy, whereas 15
(37%) patients after AC underwent manual lymph drainage, and 3 of them also
wore a compression sleeve (p<0.001). A similar increase in arm circumference
(LE%) was observed in both patient groups one year after surgery.
Patients in the AC group more often reported edema in the breast area (23 vs.
10, p<0.001) and in the upper extremity (30 vs. 5, p<0.001) than did those in
the SNB group (Table 14).
Table 14: Need for lymph therapy, increase in arm circumference (LE%), and self-
reported lymph edema one year after sentinel node biopsy (SNB) alone or axillary
clearance (AC)
Event SNB AC
N=43 (%) N= 40 (%)
Lymph therapy *
None 43 (100%) 25 (63%)
Manual lymph drainage 0 (0%) 12 (30%)
Manual lymph drainage
plus compression sleeve 0 (0%) 3 (7%)
Increase in arm circumference (LE%)
0–5% 37 (86%) 32 (80%)
5–10% 4 (10%) 5 (13%)
> 10% 1 (2%) 3 (7%)
Missing data 1 (2%) 0 (0%)
Self-reported breast oedema #
None 32 (75%) 17 (42%)
Mild 7 (16%) 16 (41%)
Moderate 3 (7%) 6 (15%)
Severe 0 (0%) 1 (2%)
Missing data 1 (2%) 0 (0%)
Self-reported arm oedema *
None 36 (84%) 9 (23%)
Mild 4 (9%) 21 (53%)
Moderate 1 (3,5%) 7 (1%)
Severe 0 (0%) 2 (5%)
Missing data 1 (3,5%) 1 (2%)
*p<0.001, #p<0.01
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Interference of postoperative morbidity with daily life
(Study V)
Arm morbidity affected work (p<0.01), hobbies (p<0.01), and daily life in gen-
eral (p<0.01) more often after AC than after SNB. The interference reported was
always mild after SNB alone. Patients had no difficulties in eating, combing their
hair, brushing teeth, dressing, or fastening a seat belt with the ipsilateral arm,
regardless of axillary treatment. Carrying bags on the operated side was difficult
for 11 (28%) patients in the AC group and for one single patient in the SNB
group (p<0.01). In the AC group, nine patients (23%) and in the SNB group
three (7%) could not sleep on the ipsilateral side (p=ns).
Work aggravated pain in the ipsilateral upper extremity more often in the AC
group, in 15 patients (37%), than after SNB, in six (15%) (p<0.05). Work, nee-
dlework, carrying items, and pressure from clothing were the most common
pain-inducers. Of the 83 patients, 7 (9%) experienced sleep disturbance due to
pain (Table 15).
Table 15: Interference of arm morbidity with work, hobbies, and daily life in
general one year after sentinel node biopsy (SNB) alone or axillary clearance (AC)
Interference with SNB AC
N=43(%) N=40(%)
Daily life in general *
None 35 (81%) 17 (43%)
Mild 7 (17%) 17 (43%)
Moderate 0 (0%) 5 (12%)
Severe 0 (0%) 1 (2%)
Missing data 1 (2%) 0 (0%)
Sleeping on the ipsilateral side
No 3 (7%) 9 (23%)
Working #
None 33 (77%) 19 (48%)
Mild 9 (21%) 13 (33%)
Moderate 0 (0%) 4 (10%)
Severe 0 (0%) 3 (7%)
Missing data 1 (2%) 1 (2%)
Hobbies #
None 34 (79%) 20 (50%)
Mild 8 (19%) 14 (35%)
Moderate 0 (0%) 5 (12%)
Severe 0 (0%) 1 (2%)






The anatomical studies of Urban (1978), based on extended radical mastectomy
series, demonstrated that the breast lymphatics drain mostly, in 75% of the cases,
directly to the axilla and in 25% to the IMN. After the introduction of LS, IMN
drainage has been seen in up to 28% to 87% of all patients with breast carcinoma
(Uren et al 1995, Veronesi et al, Jansen et al 2000, Krag et al 1998, van der Ent
1999, Rahusen 2000, Valdés-Olmos et al 2001, Estourgie et al 2003, Estourgie
et al 2004) The visualization rate of SN has varied between 75% to 99% in the
axilla and from 8% to 87% outside the axilla, when intra- or peritumoral injection
techniques were used (Borgstein et al 1998, Krag et al 1998, O’Hea et al 1998,
Haigh et al 2000, Jansen et al 2000, van der Ent et al 2001, Uren et al 2001,
Valdés-Olmos et al 2001, Estourgie et al 2003, Estourgie et al 2004). In recent
as in earlier studies, the SNs have been located solely outside the axilla in only a
few cases (Krag et al 1998, Jansen et al 2000, van der Ent et al 2001).
The particle sizes of radionuclides and doses and volumes of the tracers have a
marked effect on the visualization of SNs and especially regarding SNs outside the
axilla (Valdés-Olmos et al 2001, Leppänen et al 2002). Furthermore, lymph flow is
influenced by individual factors like physical exercise, medication, and the status of
hydration of the patients; these may influence the visualization of SNs in the LS
(Borgstein et al 1998, Krag et al 1998 Jansen et al 2000, Nieweg et al 2001b).
The reported prevalence of IMN metastases in breast cancer patients has been
17% to 25% (Jansen et al 2000, Galimberti et al 2002, Estourgie et al 2004).
Metastases in the internal mammary chain associate strongly with axillary metas-
tasis and large tumor size, and IMN metastases alone are present in 9% to 14% of
the patients  (Morrow 1981, Veronesi et al 1985, Lacour et al 1983, Noguchi et
al 1991, Galimberti et al 2002, Estourgie et al 2004). The high prevalence of
IMN metastases in reports from the late 70´s and early 80´s (Veronesi et al 1985,
Lacour et al 1983, Donegan et al1977) probably does not represent the situation
nowadays, when patients undergoing lymphatic mapping and SNB include a
high proportion at stage T1 without axillary involvement.  Even the introduc-
tion of and increasingly routine lymphatic mapping and SNB have broadened
procedures towards IMN harvesting and better nodal staging (Galimberti et al
2002, Estourgie et al 2003, Estourgie et al 2004).
Before the introduction of SNB, the investigators considered the extra axillary
nodes to be present in the first two intercostal spaces (Donegan et al 1977, Noguchi
et al 1991) and thus biopsied nodes only from the first two intercostal spaces. In
a multicentre non-sentinel study by Lacour and co-workers, the number of IMN
examined was relatively small, the median number being only 1.9 to 4.1 (Lacour
et al 1983).
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Our study, like the study of van der Ent (2001,) confirmed that the most
common site of lymphatic drainage in the internal mammary chain was the third
intercostal space.
Findings on the location of IMN metastases by Noguchi and co-workers (1991)
and on lymphatic drainage patterns to the internal mammary chain in both the
study of van der Ent and co-workers (2001) and the present study are contradic-
tory. This, as well as the limited number of IMN examined earlier (Donegan
1977, Lacour et al 1983) opens the speculation the prevalence and the location
of internal mammary metastases in breast cancer patients.
Reappraisal of IMN metastases as a prognostic factor and the findings of re-
cent publications of trials evaluating the value of postmastectomy radiation in-
cluding internal mammary field radiation have initiated discussion concerning
adoption of routine elective IMN irradiation. A small survival benefit has been
gained by including the IMN in the RT field in patients with mediocentrally
located tumors and axillary metastases (Overgaard et al 1997, Ragaz et al 1997,
Freedman et al 2000). It should be remembered, based on ours and previous
studies, that lymphatic drainage or lymph node metastases can occur irrespective
of tumor location; the location of the tumor thus cannot be the main indication
in decision-making as to IMN-field RT (Donegan et al 1977, Lacour et al 1983,
Veronesi et al 1985, Borgstein et al 1998, Uren et al 1995, van der Ent et al
2001, Estourgie et al 2004).
Furthermore, the nonpalpable tumors, regardless of quadrant, more frequently
have their drainage towards the IMNs (Estourgie et al 2004).  If all patients with
axillary metastases, regardless of tumor size or location, receive RT to the axilla,
the subclavicular, and the internal mammary fields, the proportion of patients
with IMN metastases not receiving RT to the IMN-field is probably negligible
(Recht et al 2001).  On the other hand, by this treatment strategy, a substantial
proportion of patients will receive needless extensive radiation and become pre-
disposed to the risks from irradiation such as cardiac toxicity (Freedman et al
2000). The introduction of LS and SNB has provided better tools for the diag-
nosis of regional lymph node status and maybe also tools for decision-making
regarding adjuvant treatments.  Methods for more accurately targeting the IMN-
field RT are therefore urgently needed.
Harvesting of the SN outside the axilla is more demanding, with a success rate
of 78% in the present study and 63% to 73% in previous studies (Jansen et al
2000, van der Ent et al 2001), compared to SNB in the axilla with a practically
100% retrieval rate, when the nodes are visualized in LS. Insufficient uptake of
the tracer and/or difficult anatomic circumstances cause most of the harvesting
failures (Jansen et al 2000).  Severe complications, however, seem to be rare (Jansen
et al 2000, Galimberti et al 2002).
Improved nodal staging includes also the status of SNs outside the axilla.
Surgeons, radiotherapists, and medical oncologists should consider the implica-
tions of the presence or absence of metastatic disease in the nodes. Knowing the
status of these extra-axillary SNs will lead to better selection of those who will
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benefit from adjuvant systemic treatment and maybe also postoperative RT to the
IMN chain.
Radioguided occult lesion localization
In breast conserving surgery, estimation of the free tissue margins may be diffi-
cult even when the tumor is palpable.  Excision of a nonpalpable tumor with
adequate margins by guidance of a wire is much more challenging, because of
frequent displacement of the wire. The use of a gamma probe makes easier to
control of the tumor edges, because the radioactivity clearly decreases outside the
tumor (Zurrida et al 1998). Furthermore, residual radioactivity is easy to check
from the wound to ensure that the tumor is resected radically (Zurrida et al
1998).
In the present study, close or involved margins were observed in less than 10%
of our ROLL specimens. The closest free margin was at least 10 mm in almost
70% of the cases. Gray and co-workers (2001) achieved initial margins of over 1
mm for 75% of patients, while Feggi and co-workers (2001) obtained free mar-
gins of over 3 mm in 95% of in their quadrantectomy specimens, and Gallegos
Hernandez and co-workers (2004) obtained adequate margins for 83% after the
completion of the primary operation.
ROLL has been compared with wire localization (Gray et al 2001, Luini et al
1999, Gallegos Hernandez et al 2004), and all these studies concluded that ROLL
was quite a quick, easy, and accurate method for a surgeon to find an occult
breast lesion. Furthermore, ROLL allows for a reduced excision volume and bet-
ter lesion centering within the specimen compared to those of wire localization
(Luini et al 1999, Gallegos Hernandez et al 2004).
In the present study, involved or close margins, and on the other hand, also
excessively wide margins were encountered more often with the use of WGR than
with ROLL or surgery for palpable lesions. However, a reliable comparison be-
tween results obtained by ROLL and wire localization is unfortunately not pos-
sible on the basis of our findings. The subgroup of patients operated on with use
of a guide wire was small and selected. The proportion of cases with pure ductal
invasive in situ or invasive carcinoma with an extensive invasive component was
high compared with other patient groups. Gallegos Hernandez and co-workers
found decreasing pathological diameter, increasing weight of the specimen, and
absence of microcalcifications or carcinoma in situ to be predictive factors for
clear margins. Thus, the differences observed between ROLL and wire localiza-
tion may reflect the different nature of tumors visible or invisible in breast US,
not only the differences between two localization methods.
Only a couple of previous studies have addressed the feasibility of ROLL in
connection with LS and SNB (Tanis et al 2001, Feggi et al 2001). We, as authors
of previous studies, have found the simultaneous performance of ROLL and SNB




It is not surprising that the new method, SNB, turned out to be the most expen-
sive alternative for axillary staging. At the beginning of its introduction, new
methods and procedures are associated with elevated costs due to the special
equipment and examinations necessary for successful performance of the meth-
od. Gemignani et al (2000) found SNB to be less costly than ALND because of
the shorter hospital stay after SNB. Only patients with a low probability of
axillary metastases, those with T1 tumors, were included in their study. Their
lower false-negative rate (4–9%) in frozen section diagnosis also resulted in lower
costs for SNB in relation to diagnostic ALND; a large majority (73%) of SNB
patients with tumor-negative findings in frozen section were discharged the same
day, and their postoperative hospital stays were shorter in general (Gemignani et
al 2000). We discharge our own axillary node-negative SNB patients the follow-
ing day, because of postoperative nursing care, counseling and physiotherapy.
SNB as an initial outpatient procedure under local anesthesia would have been
the most tempting alternative for SNB, at least from a theoretical standpoint. After
the initial procedure, the histopathological report of SNs would be final, meaning
that the patient would come to the subsequent breast operation with axillary stag-
ing already performed. However, according to our calculations, this would be the
most expensive alternative, probably due to the numerous operations. Moreover,
based on our clinical experience, AC as a second operation seems to be more de-
manding and laborious because of scar formation after SNB and because sparing
the intercostobrachial nerves in the second procedure may be difficult.
From the economic point of view, frozen section analysis of SNs is probably
the most crucial part of the whole procedure. Frozen section diagnostics is ex-
pensive due to the substantial workload in the pathology laboratory, but it al-
lows AC for most axillary node-positive patients during the primary operation.
A false-negative result leads to re-operation and elevated costs of surgical treat-
ment. Recovery, including sick leave, will be longer and the risk for post–opera-
tive morbidity may be higher after two procedures. The sensitivity analysis re-
vealed that frozen section diagnosis seems to be economically worthwhile as long
as the false-negative rate does not exceed 35%, which is far higher than the rate
observed in our clinic.
The lower costs of a shorter hospital stay may not fully compensate for the
costs of LS and the histological evaluation of SN; economic justification of the
method has to be sought from the wider social aspects such as decreased postop-
erative morbidity and recovery time. SNB is associated with less early postopera-
tive morbidity than is AC, and thus the return to work should be quicker. We
therefore tried to evaluate the differences in sick leaves, but the length of the sick
leave appeared to be dependent more on psychosocial factors than simply on
physical recovery from surgery. Postoperative sick leave often continued until the
end of adjuvant chemo- and/or radiotherapy because of factors like adverse ef-
fects of treatment, the patient’s psychological status, and distance between the
residence and the Department of Oncology.
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For these reasons, the most significant advantage of SNB will probably be
declining long-term morbidity. As regards chronic post-mastectomy pain and
lymphedema, the results from the present and previous studies are encouraging
(Schrenk et al 2000, Miguel et al 2001, Sener et al 2001, Burak et al 2002,Haid
et al 2002). However, larger studies with longer follow-up periods are needed
until the real benefits of SNB can be determined. Patients have to be followed up
for several years, with detailed data recorded regarding need for physiotherapy
due to arm morbidity, periods of sick leave, and change in work place or in work
responsibilities, or both. However, these work-related events are irrelevant for a
substantial percentage of breast cancer patients because they are already retired
due to old age or disability caused by other conditions. Anyway, physiotherapy
and especially the treatment of severe chronic lymphedema are expensive and con-
cern all breast cancer patients, irrespective of age and working status.
Comparison of the costs of different procedures is demanding, and the results
may not be generalizeable, for instance due to differences in treatment practices
and unit costs of resources and services (Gemignani et al 2000, Palit et al 2000).
The applicability of our results to other units thus depends on factors like the
costs of the LS and inpatient care, as well as salaries of the pathologists, surgeons,
and nurses. In addition, the length of hospital stay after SNB or ALND, the
success rate in identification of SN, and the false-negative rate in frozen-section
diagnosis vary not only between different units but may also vary over time in the
same hospital. For example, our clinic’s SN identification rate has improved from
the reported 86% and is nowadays practically 100%.
The reliability of our results may be disputed because our patients were not
randomized to the different axillary staging alternatives (ALND, SNB as day-case
surgery, SNB with and without intraoperative diagnosis). The costs of SNB with
frozen section reflect actual costs, but the costs for the hypothetical strategies
were only estimated and may therefore differ from the actual ones at least in some
respects. In addition, we assumed all patients to be eligible for SNB as day-case
surgery under local anesthesia. Because the costs of LS as well as those of the
operations and histopathological assessments of breast and axillary lymph node
specimens are averages based on a large number of cases, only the length of hos-
pital stay and possible complications after various axillary staging modalities leave
room for speculation. Because the shortest possible postoperative hospital stay
was applied when estimating the costs of the hypothetical strategies, actual costs
might be somewhat higher if several patients needed a longer stay after AC. It is,
however, unlikely that the hospital costs of diagnostic ALND exceed those of
SNB, at least when all patients eligible for SNB are considered. SNB may also be
less expensive than ALND in patients with a very low probability of axillary me-
tastases (Gemignani et al 2000).
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Postoperative lymphedema
The symptoms and signs of breast lymphedema are well known, but its etiology
is still obscure (Clarke et al 1982, Meek et al 1998). Postoperative edema can be
divided into early and late onset. Edema is considered as early, when it develops
within the first 2 months, whereas late breast edema occurs about 20 months
after surgery and RT, or after either one alone. (Clarke et al 1982). Breast surgery
as well as RT to the breast or to the axilla, or both, can disturb the lymphatic
circulation of the breast. (Clarke et al 1982). Risk for postoperative breast lymph-
edema seems to be higher in obese patients with surgery for an upper outer
quadrant tumor (Schrenk et al 2000).
According to the findings of the present and the previous studies, approxi-
mately one patient in three suffers from breast edema one year after surgery (Clarke
et al 1982, McCormick et al 1989). Breast edema seems undoubtedly to be relat-
ed to the extent of axillary surgery. After axillary sampling, Clarke and co-work-
ers (1982) observed breast lymph edema in 25% of their patients, a finding in
close agreement with our 23% prevalence of breast edema after SNB without
further axillary treatment. Breast edema was observed clearly more often, in 35%
to 79% of the patients, after AC in the present study and than that observed by
Clarke and co workers (Clarke et al 1982), who found risk for breast edema with-
out any axillary surgery to be about 6%. (Clarke et al 1982)
Adjuvant breast RT is another risk factor for breast lymphedema. Senofsky
and co-workers (1991) observed a 21% incidence of breast edema after breast
resection and RT, but incidence of breast edema was only 6% among non-irradi-
ated patients. The influence of breast RT on risk for breast edema was not as-
sessed in the present study, because practically all our patients received adjuvant
breast RT.
It is insufficiently clear whether addition of RT to the axillary and supraclavic-
ular fields after AC further elevates risk for breast edema. In the present study,
patients with tumor-positive axillary nodes, all of whom received RT also to the
axillary and the supraclavicular fields, manifested more breast edema. Whether
the reason for increased breast morbidity in this patient group was the more
extensive RT or the axillary node involvement itself, or both, could not be con-
cluded on the basis of our findings. Another possible explanation for the more
prevalent breast edema in patients with AC and involved axillary nodes is the 3-
month shorter period between completion of RT and clinical and US examina-
tion. The timing of RT in relation to the US examination may also have influ-
enced our findings concerning skin thickness of the operated breast.
The location of the tumor in the breast may also influence the prevalence of
breast lymphedema (Temple et al 2002, Schrenk et al 2000). Especially delayed
breast cellulitis, the most severe form of breast lymphedema, seems to be com-
mon in patients with tumor in the upper lateral breast segment and breast con-
serving treatment (Temple et al 2002). However, in the present study, location of
the tumor in the breast had no influence on the prevalence of breast lymphede-
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ma. None of the our patients had delayed breast cellulitis, but only milder forms
of breast lymphedema. In addition, all of our patients underwent axillary sur-
gery, SNB, or AC. Although SNB is less extensive than AC, it is also an invasive
procedure disrupting lymphatics draining from the breast to the axilla. Precise
evaluation of the role of the location of the resection in the breast requires a
patient group with breast surgery without any axillary procedure.
In addition to the varying extent and timing of RT, our results may be biased
because of the small study population and the non-randomized study setting as
regards AC and SNB. Other confounding factors like systemic adjuvant therapy,
age, and body mass index of the patients have also possibly influenced our results.
Despite the limitations of our study, our results as well as those of the Clarke and
co-workers (1982) indicate, however, that the extent of the axillary procedure
elevates the risk for breast lymphedema.
Few simple objective methods exist for evaluation of post-treatment symp-
toms in the upper extremity and especially those in the breast. In addition to the
clinical examination, we evaluated the breasts with US and compared the operat-
ed breast to the non-operated one. The US findings were concordant with those
of the clinical examination. Furthermore, the thickness of the skin and the amount
of interstitial fluid was similar on the non-operated side in all three treatment
groups.  For these reasons breast US seems clearly to be a feasible method for
evaluation of breast edema.
Postoperative upper extremity functional disorders
Restricted shoulder motion was more common 2 weeks after AC, as reported in
our study examining early postoperative morbidity in these same patients (Lei-
denius et al 2003). Peintinger (2003) also shows less motion restriction in favor
of SNB.
A slight but not significant difference in shoulder abduction and flexion, as
well as self-reported shoulder stiffness was evident after SNB and AC also at the
end of the study period. Muscle weakness in the ipsilateral arm was reported more
frequently after more extensive axillary treatment. It is difficult to distinguish
whether such symptoms are due to breast or axillary surgery, adjuvant radio- or
chemotherapy, or musculosceletal disorders unrelated to breast cancer treatment.
It is noteworthy that almost one patient in every three already had restricted
shoulder motion before surgery. Strain in the pectoral muscle was a common
complaint after but also before the operation. In addition, two SNB-group pa-
tients fell and hurt the ipsilateral shoulder just before the one-year follow-up. For
these reasons, the real incidence of axillary surgery-related functional disorders is
difficult to estimate. Knowledge of preoperative status as to range of motion is
crucial in evaluating the influence of axillary treatment.
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Postoperative upper extremity sensory disorders
The cause of upper arm sensory disorders is suggested to be transsection of or
injury to the intercostobrachial nerve (Freeman et al 2003). This causes impair-
ment of skin sensation in the area of the axilla and upper arm and can also lead to
an edematous sensation in the upper arm. This kind of nerve injury is more
probable after AC than after SNB. The present and the other studies (Peinttinger
et al, Temple et al 2002, Burak et al 2002) show that sensory disorders are more
common after AC than after SNB.
During the first 6 postoperative months, skin sensation, tested by von Frey
filament stimulation, was significantly altered after AC compared to that after
SNB. Improvement in sensation back to the preoperative level was recorded dur-
ing the one-year follow-up in almost all patients regardless of the extent of axil-
lary treatment, probably due to the recovery of spared sensory nerves. However,
at the end of follow-up, pain and self- reported sensory disorders like numbness
and strange sensations in the ipsilateral arm were still common, especially after
extensive axillary treatment. One-fourth of the patients in the SNB group report-
ed mild or moderate pain or sensory disorders in the arm, but none of them
suffered severe pain, numbness, or strange sensations. On the other hand, some
patients also in the SNB group experienced pain, with daily need for medication.
Unfortunately, the data did not differentiate among the locations of bothersome
pain, in the breast operation area, arm, or both.
Postoperative lymphedema
Measurement of lymphedema is challenging, because it lacks simple, objective,
reliable methods (Gerber et al 1998, Rampaul et al 2003). Distinguishing be-
tween the lymph edema-causative or -associative factors – extent of breast and
axillary surgery, RT, BMI, or infection – is not easy.
Most of the studies evaluate lymphedema by measuring the circumference of
the arm at several points (Schrenk et al 2001, Golshan et al 2003) and define
lymphedema as an increase in circumference of at least 2 cm compared with pre-
operative status or the contralateral arm (Sener et al 2001, Schrenk et al 2001).
This could be misleading, if factors such as BMI of the patient, change in the
weight and location of the lymphedema in the arm, muscle wasting due to de-
creased use of the ipsilateral arm, strenuous exercise using the affected arm, recent
manual lymphatic draining, and the use of a compression sleeve are not taken
into account. Nor are measurement points using bony protuberances as land-
marks exact. In addition, a 2-cm change in arm circumference is certainly signif-
icant in a very slim patient but hardly noticeable in an obese one. Probably for
these reasons we found no differences in arm circumferences between groups.
This finding is in close agreement with the observations of Temple and co-work-
ers (2002). Not surprisingly, increase in arm circumference correlated poorly with
need for lymph therapy or self-experienced lymphedema, even in patients with
severe edema and a compression sleeve.
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Subjective estimation of lymphedema in questionnaires may lead to over-esti-
mation and increased figures for prevalence of lymphedema. The feeling of numb-
ness and thickness due to injury of the intercostobrachial nerve may be misinter-
preted as lymphedema, leading to over-reporting. Accordingly, self-experienced
arm edema, most often mild, was a common finding in the present study, espe-
cially after extensive axillary treatment. Nevertheless, less than 15% of patients in
the SNB group complained of arm edema, and none of them experienced it as
severe. Furthermore, none of the patients with SNB alone wore a compression
sleeve or received lymph therapy. This is in agreement with recent findings of
none or only minimal risk for clinically significant lymphedema after axillary node
sampling (Rampaul et al 2003) or SNB (Blanchard et al 2003) without further
axillary treatment. For these reasons, the risk for disabling lymphedema after
SNB seems only minimal.
Interference of postoperative morbidity with daily life
Interference of arm morbidity with work, hobbies, or daily life in general was less
common and less severe after SNB alone than after more extensive axillary treat-
ment. Arm morbidity affected the daily life of about 20% of patients after SNB
alone, but the interference was mild in this patient group.
Our results are in agreement with previous reports showing faster recovery
and less postoperative morbidity after SNB alone than after more extensive axil-
lary treatment (Miguel et al 2001, Roumen et al 2001, Schrenk et al 2001, Sener
et al 2001, Burak et al 2002, Ernst et al 2002, Haid et al 2002, Temple et al
2002, Blanchard et al 2003, Gosselink et al 2003, Leidenius et al 2003, Peintinger
et al 2003, Schijven et al 2003) Regrettably, we could not estimate reliably the
influence of extent of axillary surgery on one-year postoperative morbidity, be-
cause most patients in our AC group were axillary node-positive and received RT
to the axillary and supraclavicular fields. They also received adjuvant chemother-
apy more frequently than did the mainly node-negative patients in the SNB group.
RT increases especially the risk for lymphedema after AC (Bentzen et al 2000,
Hojris et al 2000,Ververs et al 2001), but is also associated with sensory and
functional disorders (Bentzen and Dische 2000, Hojris et al 2000, Ververs et al
2001) The frequent use of adjuvant axillary RT is the most probable explanation
for the high proportion of our AC-group patients’ receiving lymph therapy.
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Conclusion
SNB is a feasible method for nodal staging of breast cancer, providing informa-
tion on nodal metastases, both in the axilla and outside the axilla. Simultaneous
resection of a nonpalpable lesion in combination with SNB is possible after a
single intratumoral radioactive tracer injection without other localization meth-
ods. The results of this technique are comparable with results achieved by surgery
on palpable lesions.
SNB is a more expensive method for nodal staging than is diagnostic ALND.
However, the intra-operative diagnosis of SN metastases seems to be worthwhile
as long as the false-negative rate is relatively low. Risk for severe arm morbidity
and long-time morbidity is minimal after SNB; in particular the risk for disabling
lymph edema is negligible.
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